Labile iron: Manifestations and clinical implications

Journal of the American Society of Nephrology

Volumn 15, Issue SUPPL. 2, 2004, Pages

  Van Wyck, David B ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON; IRON DEXTRAN; IRON SACCHARATE; TRANSFERRIN;

BACTERIAL GROWTH; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISPOSITION; ELECTROPHORESIS; HUMAN; NEUTROPHIL; OXIDATIVE STRESS; PHARMACOKINETICS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 9644294211     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000143816.04446.4C     Document Type: Review

References (44)

1. Cox JSG, King RE: Valency investigations of iron dextran (Imferon). Nature 207: 1202-1203, 1965
2. Hatton RC, Portales IT, Finlay A, Ross EA: Removal of iron dextran by hemodialysis: An in vitro study. Am J Kidney Dis 26: 327-330, 1995
3. Manuel MA, Stewart WK, Clair Neill GD, Hutchinson F: Loss of iron-dextran through cuprophane membrane of a disposable coil dialyser. Nephron 9: 94-98, 1972
4. Calvar C, Mata D, Alonso C, Ramos B, Lopez dN: Intravenous administration of iron gluconate during haemodialysis. Nephrol Dial Transplant 12: 574-575, 1997
5. Kooistra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC, Marx JJ: Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 32[Suppl 1]: 36-41, 2002
6. Ferrlecit Product Package Insert, Coarona, CA, Watson Pharmaceuticals, Inc., 2001
7. Manley HJ, Grabe DW: Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: An in-vitro study. BMC Nephrol 5: 1, 2004
8. Van Wyck DB, Anderson J, Johnson K: Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 19: 561-563, 2004
9. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15: 1827-1834, 2000
10. Seligman PA, Schleicher RB, Pringle J: Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 45: 898-901, 1999
11. McIntosh ME, Lynn JK, Meyerriecks N, Contant I: Serum iron determination in patients receiving therapy with iron dextran ("Imferon"). Clin Chem 22: 524-527, 1976
12. Huisman W: Interference of Imferon in colorimetric assay for iron. Clin Chem 26: 635-637, 1980
13. Sekiguchi M, Watanabe N, Osanai N, Kumasaka K, Tsuchiya T, Kawano K, Morita K: Determination of serum iron by electro-analytical method-studies on methodologic differences in values for serum iron. Rinsho Byori 28: 907-910, 1980
14. Milman N: Iron therapy in patients undergoing maintenance hemodialysis. Acta Med Scand 200: 315-319, 1976
15. Jacobs JC, Alexander NM: Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem 36: 1803-1807, 1990
16. Zanen AL, Adriaansen HJ, van Bommel EJH, Posthuma R, de Jong GMT: Oversaturation of transferrin after intravenous ferric gluconate in haemodialysis patients. Nephrol Dial Transplant 11: 820-824, 1996
17. Sunder-Plassmann G, Horl WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 11: 1797-1802, 1996
18. Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32[Suppl 1]: 9-16, 2002
19. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI: The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 95: 2975-2982, 2000
20. Esposito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 32[Suppl 1]: 42-49, 2002
21. von Bonsdorff L, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J: Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies. Clin Chem 48: 307-314, 2002
22. Geisser P, Baer M, Schaub E: Structure/histotoxicity relationship of parenteral iron preparation. Arzneim Forsch 42: 1439-1452, 1992
23. Henderson PA, Hillman RS: Characteristics of iron dextran utilization in man. Blood 34: 357-375, 1969
24. Kind CN: The measurement of serum unsaturated iron-binding capacity in the presence of iron-dextran. Ann Clin Biochem 25: 325-326, 1988
25. Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H: Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 65: 1973-1978, 2003
26. Sturm B, Goldenberg H, Scheiber-Mojdehkar B: Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem 270: 3731-3738, 2003
27. Masini A, Trenti T, Ceccarelli D, Muscatello U: The effect of a ferric iron complex on isolated rat-liver mitochondria. III. Mechanistic aspects of iron-induced calcium efflux. Biochim Biophys Acta 891: 150-156, 1987
28. Masini A, Trenti T, Ceccarelli-Stanzani D, Ventura E: The effect of ferric iron complex on isolated rat liver mitochondria. II. Ion movements. Biochim Biophys Acta 810: 27-32, 1985
29. Masini A, Trenti T, Ceccarelli-Stanzani D, Ventura E: The effect of ferric iron complex on isolated rat liver mitochondria. I. Respiratory and electrochemical responses. Biochim Biophys Acta 810: 20-26, 1985
30. Masini A, Trenti T, Ventura E, Ceccarelli D, Muscatello U: The effect of ferric iron complex on Ca2+ transport in isolated rat liver mitochondria. Biochem Biophys Res Commun 130: 207-213, 1985
31. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: 90-103, 2002
32. Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Horl WH, Sunder-Plassmann G: Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 14: 2639-2644, 2003
33. Guo D, Jaber BL, Lee S, Perianayagam MC, King AJ, Pereira BJ, Balakrishnan VS: Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 58: 134-142, 2002
34. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH: High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64: 728-736, 2003
35. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655-663, 1998
36. Webster MH, Waitkins SA, Stott A: Impaired bacteriological responses in babies after maternal iron dextran infusion. J Clin Pathol 34: 651-654, 1981
37. Legssyer R, Geisser P, McArdle H, Crichton RR, Ward RJ: Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress. Biometals 16: 425-433, 2003
38. Salahudeen AK, Oliver B, Bower JD, Roberts LJ: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60: 1525-1531, 2001
39. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T, Shasha SM, Kristal B: Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 18: 924-930, 2003
40. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217, 2002
41. Cavdar C, Temiz A, Yenicerioglu Y, Caliskan S, Celik A, Sifil A, Onvural B, Camsari T: The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol 37: 77-82, 2003
42. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G: Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 64: 572-578, 2003
43. Kudasheva DS, Lai J, Ulman A, Cowman MK: Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorgan Biochem 98: 1757-1769, 2004
44. Sloand JA, Shelly MA, Erenstone AL, Schiff MJ, Talley TE, Dhakal MP: Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies. Perit Dial Int 18: 522-527, 1998